Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,514

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Targeting the dynamic HSP90 complex in cancer

Open access
Trepel, Jane, Mollapour, Mehdi, Giaccone, Giuseppe, Neckers, Len·2010·Nature Reviews Cancer
DOI 10.1038/nrc2887
Open this paper in CoChat — free account

Abstract

The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90. However, although recent reports of the early clinical efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2887

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 156

  1. Wandinger, S. K., Richter, K. & Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 283, 18473–18477 (2008). · DOI · Paper page
  2. Pratt, W. B. & Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228, 111–133 (2003). · DOI · Paper page
  3. Pratt, W. B., Morishima, Y. & Osawa, Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 283, 22885–22889 (2008). · DOI
  4. Zhao, R. & Houry, W. A. Hsp90: a chaperone for protein folding and gene regulation. Biochem. Cell Biol. 83, 703–710 (2005). · DOI
  5. Tariq, M., Nussbaumer, U., Chen, Y., Beisel, C. & Paro, R. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc. Natl Acad. Sci. USA 106, 1157–1162 (2009). · DOI
  6. Eccles, S. A. et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850–2860 (2008). · DOI · Paper page
  7. Chiosis, G. & Tao, H. Purine-scaffold Hsp90 inhibitors. IDrugs 9, 778–782 (2006).
  8. Kim, Y. S. et al. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9, 1479–1492 (2009). · DOI · Paper page
  9. Workman, P., Burrows, F., Neckers, L. & Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 1113, 202–216 (2007). · DOI · Paper page
  10. Pearl, L. H. & Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271–294 (2006). · DOI · Paper page
  11. Donnelly, A. & Blagg, B. S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15, 2702–2717 (2008). · DOI · Paper page
  12. Prodromou, C. & Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 3, 301–323 (2003). · DOI · Paper page
  13. Wayne, N. & Bolon, D. N. Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers. J. Biol. Chem. 282, 35386–35395 (2007). · DOI
  14. Onuoha, S. C., Coulstock, E. T., Grossmann, J. G. & Jackson, S. E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 379, 732–744 (2008). · DOI
  15. Vaughan, C. K. et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23, 697–707 (2006). This paper describes the first structure of an HSP90–co-chaperone–client protein complex. · DOI · Paper page
  16. Southworth, D. R. & Agard, D. A. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. Mol. Cell 32, 631–640 (2008). This paper reports the species-dependence of the conformational states sampled by HSP90. · DOI · Paper page
  17. McLaughlin, S. H., Ventouras, L. A., Lobbezoo, B. & Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J. Mol. Biol. 344, 813–826 (2004). · DOI
  18. Meyer, P. et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23, 1402–1410 (2004). · DOI · Paper page
  19. Mickler, M., Hessling, M., Ratzke, C., Buchner, J. & Hugel, T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nature Struct. Mol. Biol. 16, 281–286 (2009). · DOI · Paper page
  20. Hessling, M., Richter, K. & Buchner, J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nature Struct. Mol. Biol. 16, 287–293 (2009). References 26 and 27 dissect the conformational intermediates of the HSP90 chaperone cycle. · DOI · Paper page
  21. Panaretou, B. et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 10, 1307–1318 (2002). · DOI · Paper page
  22. Retzlaff, M. et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol. Cell 37, 344–354 (2010). · DOI · Paper page
  23. Koulov, A. V. et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol. Biol. Cell 21, 871–884 (2010). This paper describes how AHA1 interaction with HSP90 affects client interaction with the HSP90 complex and chaperone efficiency. · DOI · Paper page
  24. Miyata, Y. & Nishida, E. Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol. Cell. Biochem. 316, 127–134 (2008). · DOI
  25. Smith, J. R. & Workman, P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 8, 362–372 (2009). · DOI
  26. Pratt, W. B., Morishima, Y., Murphy, M. & Harrell, M. Chaperoning of glucocorticoid receptors. Handb. Exp. Pharmacol. 172, 111–138 (2006). · DOI · Paper page
  27. Zhang, M. et al. Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J. 27, 2789–2798 (2008). · DOI
  28. Boulon, S. et al. The Hsp90 chaperone controls the biogenesis of L7Ae RNPs through conserved machinery. J. Cell Biol. 180, 579–595 (2008). · DOI · Paper page
  29. Vaughan, C. K. et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 31, 886–895 (2008). · DOI · Paper page
  30. McDowell, C. L., Bryan Sutton, R. & Obermann, W. M. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int. J. Biol. Macromol. 45, 310–314 (2009). · DOI
  31. Gray, P. J. Jr, Stevenson, M. A. & Calderwood, S. K. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67, 11942–11950 (2007). · DOI
  32. Holmes, J. L., Sharp, S. Y., Hobbs, S. & Workman, P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 68, 1188–1197 (2008). · DOI
  33. Scroggins, B. T. & Neckers, L. Post-translational modification of heat shock protein 90: impact on chaperone function. Expert Opin. Drug Discov. 2, 1403–1414 (2007). · DOI
  34. Mimnaugh, E. G., Worland, P. J., Whitesell, L. & Neckers, L. M. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J. Biol. Chem. 270, 28654–28659 (1995). · DOI
  35. Wandinger, S. K., Suhre, M. H., Wegele, H. & Buchner, J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 25, 367–376 (2006). · DOI
  36. Duval, M., Le Boeuf, F., Huot, J. & Gratton, J. P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 18, 4659–4668 (2007). This paper reports the tyrosine phosphorylation of HSP90 by a client kinase. · DOI
  37. Kurokawa, M., Zhao, C., Reya, T. & Kornbluth, S. Inhibition of apoptosome formation by suppression of Hsp90β phosphorylation in tyrosine kinase-induced leukemias. Mol. Cell. Biol. 28, 5494–5506 (2008). · DOI
  38. Old, W. M. et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol. Cell 34, 115–131 (2009). · DOI
  39. Lees-Miller, S. P. & Anderson, C. W. Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J. Biol. Chem. 264, 2431–2437 (1989). · DOI
  40. Harvey, S. L., Charlet, A., Haas, W., Gygi, S. P. & Kellogg, D. R. Cdk1-dependent regulation of the mitotic inhibitor Wee1. Cell 122, 407–420 (2005). · DOI · Paper page
  41. Mollapour, M. et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell 37, 333–343 (2010). · DOI · Paper page
  42. Mollapour, M., Tsutsumi, S. & Neckers, L. Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 9, 1–7 (2010). · doi:10.4161/cc.9.1.10357
  43. Yang, Y. et al. Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion. Cancer Res. 68, 4833–4842 (2008). · DOI · Paper page
  44. Maloney, A. et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239–3253 (2007). · DOI
  45. Martinez-Ruiz, A. et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc. Natl Acad. Sci. USA 102, 8525–8530 (2005). · DOI · Paper page
  46. Morra, G., Verkhivker, G. & Colombo, G. Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput. Biol. 5, e1000323 (2009). · DOI
  47. Retzlaff, M. et al. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 10, 1147–1153 (2009). · DOI · Paper page
  48. Compton, S. A., Elmore, L. W., Haydu, K., Jackson-Cook, C. K. & Holt, S. E. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells. Mol. Cell. Biol. 26, 1452–1462 (2006). · DOI
  49. Toogun, O. A., Dezwaan, D. C. & Freeman, B. C. The hsp90 molecular chaperone modulates multiple telomerase activities. Mol. Cell. Biol. 28, 457–467 (2008). · DOI
  50. Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z. & Nardai, G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79, 129–168 (1998). · DOI · Paper page
  51. Conzen, S. D. Minireview: nuclear receptors and breast cancer. Mol. Endocrinol. 22, 2215–2228 (2008). · DOI
  52. Echeverria, P. C. & Picard, D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim. Biophys. Acta 1803, 641–649 (2009). · DOI · Paper page
  53. Zou, J., Guo, Y., Guettouche, T., Smith, D. F. & Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471–480 (1998). · DOI · Paper page
  54. Conde, R., Belak, Z. R., Nair, M., O'Carroll, R. F. & Ovsenek, N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem. Cell Biol. 87, 845–851 (2009). · DOI
  55. Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005–1018 (2007). · DOI · Paper page
  56. Min, J. N., Huang, L., Zimonjic, D. B., Moskophidis, D. & Mivechi, N. F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26, 5086–5097 (2007). References 69 and 70 highlight the importance of HSF1 for carcinogenesis. · DOI
  57. Au, Q., Zhang, Y., Barber, J. R., Ng, S. C. & Zhang, B. Identification of inhibitors of HSF1 functional activity by high-content target-based screening. J. Biomol. Screen. 14, 1165–1175 (2009). · doi:10.1177/1087057109347472
  58. Ci, W. et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 113, 5536–5548 (2009). · DOI · Paper page
  59. Cerchietti, L. C. et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397–3405 (2009). · DOI · Paper page
  60. Cerchietti, L. C. et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Med. 15, 1369–1376 (2009). · DOI · Paper page
  61. Choo, A. et al. The role of IRF1 and IRF2 transcription factors in leukaemogenesis. Curr. Gene Ther. 6, 543–550 (2006). · DOI
  62. Narayan, V., Eckert, M., Zylicz, A., Zylicz, M. & Ball, K. L. Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery. J. Biol. Chem. 284, 25889–25899 (2009). · DOI
  63. Bach, C. & Slany, R. K. Molecular pathology of mixed-lineage leukemia. Future Oncol. 5, 1271–1281 (2009). · DOI
  64. Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P. & Sif, S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 24, 9630–9645 (2004). · DOI · Paper page
  65. Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biol. 6, 731–740 (2004). This paper reports that HSP90 inhibitor treatment suppresses SMYD3 activity in cancer cells. · DOI · Paper page
  66. Komatsu, S. et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139–1146 (2009). · DOI
  67. Abu-Farha, M. et al. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 7, 560–572 (2008). · DOI · Paper page
  68. Sekimoto, T. et al. The molecular chaperone Hsp90 regulates accumulation of DNA polymerase η at replication stalling sites in UV-irradiated cells. Mol. Cell 37, 79–89 (2010). · DOI
  69. Specchia, V. et al. Hsp90 prevents phenotypic variation by suppressing the mutagenic activity of transposons. Nature 463, 662–665 (2010). · DOI · Paper page
  70. Brennecke, J. et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell 128, 1089–1103 (2007). · DOI · Paper page
  71. Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940–7946 (2008). · DOI
  72. Yano, A. et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl Acad. Sci. USA 105, 15541–15546 (2008). · DOI
  73. Zoubeidi, A. et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67, 10455–10465 (2007). · DOI · Paper page
  74. Solit, D. B. et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14, 8302–8307 (2008). · DOI · Paper page
  75. Grbovic, O. M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA 103, 657–662 (2006). · DOI · Paper page
  76. da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686–10691 (2005). · DOI
  77. Mimnaugh, E. G., Chavany, C. & Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796–22801 (1996). · DOI · Paper page
  78. Modi, S. et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J. Clin. Oncol. Abstr. 26, 1027 (2008). · doi:10.1200/jco.2008.26.15_suppl.1027
  79. Xu, W. et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br. J. Cancer 97, 741–744 (2007). · DOI
  80. Chandarlapaty, S. et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325–334 (2009). · DOI
  81. Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106, 8368–8373 (2009). · DOI · Paper page
  82. Richardson, P. G. et al. Tanespimycin + bortezomib demonstrates safety, activity, and effective target inhibition in relapsed/refractory myeloma patients: updated results of a phase 1/2 study. 51st Am. Soc. Hematogy Annu. Meet. Abstr. (2009). · DOI
  83. Mimnaugh, E. G., Xu, W., Vos, M., Yuan, X. & Neckers, L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol. Cancer Res. 4, 667–681 (2006). · DOI
  84. Mitsiades, C. S. et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107, 1092–1100 (2006). · DOI · Paper page
  85. Frebel, K. & Wiese, S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 34, 1287–1290 (2006). · DOI
  86. Fionda, C. et al. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J. Immunol. 183, 4385–4394 (2009). This paper shows that HSP90 inhibitors enhance NK-dependent recognition and lysis of myleoma cells in an HSF1-dependent manner. · DOI
  87. Tse, A. N., Sheikh, T. N., Alan, H., Chou, T. C. & Schwartz, G. K. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol. Pharmacol. 75, 124–133 (2009). · DOI
  88. Arlander, S. J. et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J. Biol. Chem. 281, 2989–2998 (2006). · DOI
  89. Tse, A. N. et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 14, 6704–6711 (2008). · DOI
  90. Hubbard, J. et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest. New Drugs 15 Jan 2010 [epub ahead of print]. · DOI
  91. Hwang, M., Moretti, L. & Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 16, 3081–3092 (2009). · doi:10.2174/092986709788802999
  92. Reikvam, H., Ersvaer, E. & Bruserud, O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets 9, 761–776 (2009). · doi:10.2174/156800909789271486
  93. Lancet, J. E. et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022,17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699–705 (2010). · DOI
  94. Weisberg, E. et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updat. 12, 81–89 (2009). · DOI
  95. Shiotsu, Y. et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96, 2284–2291 (2000). · DOI
  96. Peng, C., Li, D. & Li, S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 6, 2227–2231 (2007). · DOI
  97. O'Hare, T., Eide, C. A. & Deininger, M. W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin. Investig. Drugs 17, 865–878 (2008). · DOI
  98. Peng, C. et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110, 678–685 (2007). · DOI
  99. Castro, J. E. et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106, 2506–2512 (2005). · DOI
  100. Elfiky, A. et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J. Clin. Oncol. Abstr. 26, 2503 (2008). · doi:10.1200/jco.2008.26.15_suppl.2503
  101. Gallegos Ruiz, M. I. et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE 3, e0001722 (2008). · DOI
  102. Sequist, L. V. et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J. Clin. Oncol. Abstr. 27, 8073 (2009). · doi:10.1200/jco.2009.27.15_suppl.8073
  103. Shimamura, T. & Shapiro, G. I. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol. 3, S152–S159 (2008). · DOI
  104. Shimamura, T. et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 68, 5827–5838 (2008). · DOI
  105. Banerji, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152–4161 (2005). · DOI · Paper page
  106. Grem, J. L. et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23, 1885–1893 (2005). · DOI
  107. Ramanathan, R. K. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J. Clin. Oncol. 28, 1520–1526 (2010). · DOI
  108. Eiseman, J. L. et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55, 21–32 (2005). · DOI
  109. Vilenchik, M. et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 11, 787–797 (2004). · DOI · Paper page
  110. Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407–410 (2003). · DOI · Paper page
  111. Kummar, S. et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 46, 340–347 (2010). · DOI
  112. Dakappagari, N. et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15, 31–38 (2009). · doi:10.3109/13547500903261347
  113. Demetri, G. D. et al. Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. J. Clin. Oncol. Abstr. 25, 10024 (2007). · doi:10.1200/jco.2007.25.18_suppl.10024
  114. Smith-Jones, P. M., Solit, D., Afroze, F., Rosen, N. & Larson, S. M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J. Nucl. Med. 47, 793–796 (2006). This paper describes a new non-invasive imaging approach to monitor anti-tumour HSP90 inhibitor activity in vivo.
  115. Oude Munnink, T. H. et al. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 46, 678–684 (2009). · doi:10.1016/j.ejca.2009.12.009
  116. Kramer-Marek, G., Kiesewetter, D. O. & Capala, J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules. J. Nucl. Med. 50, 1131–1139 (2009). · DOI
  117. Holland, J. P. et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE 5, e8859 (2010). · DOI
  118. Le, H. C. et al. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn. Reson. Med. 62, 1112–1119 (2009). · doi:10.1002/mrm.22137
  119. Chung, Y. L. et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst. 95, 1624–1633 (2003). · doi:10.1093/jnci/djg084
  120. Liu, D. et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer 87, 783–789 (2002). · doi:10.1038/sj.bjc.6600558
  121. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G. & Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 91, 1940–1949 (1999). · DOI · Paper page
  122. Guo, W. et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65, 10006–10015 (2005). · DOI · Paper page
  123. Gaspar, N. et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69, 1966–1975 (2009). · DOI
  124. Erlichman, C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin. Investig. Drugs 18, 861–868 (2009). · DOI
  125. McCollum, A. K., Teneyck, C. J., Sauer, B. M., Toft, D. O. & Erlichman, C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66, 10967–10975 (2006). · DOI
  126. Evans, C. G., Chang, L. & Gestwicki, J. E. Heat shock protein 70 (Hsp70) as an emerging drug target. J. Med. Chem. 24 Mar 2010 (doi:10.1021/jm100054f). · DOI · Paper page
  127. Powers, M. V. et al. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9, 1542–1550 (2010). · DOI · Paper page
  128. Hadchity, E. et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol. Ther. 17, 1387–1394 (2009). · doi:10.1038/mt.2009.90
  129. Prodromou, C. et al. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem. Biol. 4, 289–297 (2009). · DOI
  130. Matthews, S. B. et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 70, 27–36 (2010). · DOI
  131. Shelton, S. N. et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 76, 1314–1322 (2009). References 148 and 149 describe new C-terminal HSP90 inhibitors with potent anticancer activity. · DOI
  132. Radanyi, C. et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 274, 88–94 (2009). · DOI
  133. Zhang, T. et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7, 162–170 (2008). · DOI · Paper page
  134. Sreeramulu, S., Gande, S. L., Gobel, M. & Schwalbe, H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew. Chem. Int. Ed. Engl. 48, 5853–5855 (2009). · DOI · Paper page
  135. Chakraborty, A. et al. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl Acad. Sci. USA 105, 1134–1139 (2008). · DOI
  136. Voss, A. K., Thomas, T. & Gruss, P. Mice lacking HSP90β fail to develop a placental labyrinth. Development 127, 1–11 (2000). · DOI · Paper page
  137. Dollins, D. E., Warren, J. J., Immormino, R. M. & Gewirth, D. T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 28, 41–56 (2007). · DOI · Paper page
  138. Frey, S., Leskovar, A., Reinstein, J. & Buchner, J. The ATPase cycle of the endoplasmic chaperone Grp94. J. Biol. Chem. 282, 35612–35620 (2007). · DOI
  139. Leskovar, A., Wegele, H., Werbeck, N. D., Buchner, J. & Reinstein, J. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J. Biol. Chem. 283, 11677–11688 (2008). · DOI
  140. Immormino, R. M. et al. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J. Mol. Biol. 388, 1033–1042 (2009). · DOI
  141. Felts, S. J. et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 275, 3305–3312 (2000). · DOI · Paper page
  142. Hua, G., Zhang, Q. & Fan, Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem. 282, 20553–20560 (2007). · DOI · Paper page
  143. Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119, 454–464 (2009). · DOI · Paper page
  144. Leav, I. et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol. 176, 393–401 (2009). · DOI
  145. Sidera, K. & Patsavoudi, E. Extracellular HSP90: conquering the cell surface. Cell Cycle 7, 1564–1568 (2008). · DOI
  146. Eustace, B. K. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nature Cell Biol. 6, 507–514 (2004). This paper describes an important role for secreted HSP90 in cancer cell motility and invasion. · DOI · Paper page
  147. Becker, B. et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 13, 27–32 (2004). · DOI · Paper page
  148. Tsutsumi, S. et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27, 2478–2487 (2008). · DOI · Paper page
  149. Cheng, C. F. et al. Transforming growth factor alpha (TGFα)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFβ-rich environment during wound healing. Mol. Cell. Biol. 28, 3344–3358 (2008). · DOI · Paper page
  150. Li, W. et al. Extracellular heat shock protein-90α: linking hypoxia to skin cell motility and wound healing. EMBO J. 26, 1221–1233 (2007). · DOI · Paper page
  151. Tsutsumi, S. et al. Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nature Struct. Mol. Biol. 16, 1141–1147 (2009). · DOI
  152. Sidera, K., Gaitanou, M., Stellas, D., Matsas, R. & Patsavoudi, E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem. 283, 2031–2041 (2008). · DOI
  153. Annamalai, B., Liu, X., Gopal, U. & Isaacs, J. S. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol. Cancer Res. 7, 1021–1032 (2009). · DOI
  154. Kawabe, M. et al. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res. 69, 6995–7003 (2009). · DOI
  155. Wesa, A. K. et al. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J. Immunol. 181, 7721–7727 (2008). · DOI
  156. Stuehler, C. et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114, 2829–2836 (2009). · doi:10.1182/blood-2009-06-224600

Cited by

See all 1,514

Metadata

Authors
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2010-08
Volume
10
Issue
8
Pages
537-549
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc2887
OpenAlex
W2060902443
Cited by
1,514
References
18
FWCI
6.60
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the dynamic HSP90 complex in cancer. https://app.cochat.ai/papers/10.1038/nrc2887
The paper
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010). Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer. https://doi.org/10.1038/nrc2887

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.